New drug shows promise in early liver cancer trial
NCT ID NCT04358185
First seen May 13, 2026 · Last updated Jun 08, 2026 · Updated 6 times
Summary
This early-phase study tested a drug called itacitinib in 19 adults with advanced liver cancer that had not responded to first-line treatment. The goal was to check the drug's safety and see if it could shrink tumors or slow cancer growth. Itacitinib works by blocking a protein that helps cancer spread.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for ADVANCED HEPATOCELLULAR CARCINOMA are added.
Genom att skicka in godkänner du våra Användarvillkor
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
Genom att skicka in godkänner du våra Användarvillkor
Locations
-
Imperial College Healthcare NHS Trust
London, W12 0HS, United Kingdom
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.